Global Markets
Additional European Equity News
News detail
Alzheimer's Drugs - A Cochrane review of drug trials has found that Alzheimer's drugs targeting amyloid protein buildup do not meaningfully improve or slow cognitive decline in patients with mild symptoms, despite successfully removing amyloid from the brain. The findings raise questions about medicines developed by Eli Lilly (LLY) and Eisai (ESAIY), among others, Bloomberg reports. (Bloomberg)ASML (ASML NA) price target raised to EUR 1,570 (prev. EUR 1,450) at Goldman Sachs
Related stocks
2 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.